Reassessing the two-year rodent carcinogenicity bioassay: a review of the applicability to human risk and current perspectives.

The 2-year rodent carcinogenicity test has been the regulatory standard for the prediction of human outcomes for exposure to industrial and agro-chemicals, food additives, pharmaceuticals and environmental pollutants for over 50 years. The extensive experience and data accumulated over that time has spurred a vigorous debate and assessment, particularly over the last 10 years, of the usefulness of this test in terms of cost and time for the information obtained. With renewed interest in the United States and globally, plus new regulations in the European Union, to reduce, refine and replace sentinel animals, this review offers the recommendation that reliance on information obtained from detailed shorter-term, 6 months rodent studies, combined with genotoxicity and chemical mode of action can realize effective prediction of human carcinogenicity instead of the classical two year rodent bioassay. The aim of carcinogenicity studies should not be on the length of time, and by obligation, number of animals expended but on the combined systemic pathophysiologic influence of a suspected chemical in determining disease. This perspective is in coordination with progressive regulatory standards and goals globally to utilize effectively resources of animal usage, time and cost for the goal of human disease predictability.

[1]  A. Kinsella,et al.  Long Term and Short Term Screening Assays for Carcinogens: A Critical Appraisal , 1981, British Journal of Cancer.

[2]  L. Gold,et al.  Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. , 1999, Environmental health perspectives.

[3]  N. Page,et al.  Guidelines for carcinogen bioassay in small rodents. , 1976, National Cancer Institute carcinogenesis technical report series.

[4]  John D. Walker,et al.  Use of QSARs in international decision-making frameworks to predict health effects of chemical substances. , 2003, Environmental health perspectives.

[5]  W. Fritz WHO‐IARC Monographs on the evaluation of carcinogenic risk of chemicals to humans. Supplement 2: Long‐Term and Short‐Term Screening Assays for carcinogens: A critical appraisal. 426 Seiten. International Agency for Research on Cancer, Lyon 1980. Preis: 40,‐sfrs.; 25,‐US$ , 1982 .

[6]  J A Heddle,et al.  A rapid in vivo test for chromosomal damage. , 1973, Mutation research.

[7]  E. Benfenati,et al.  A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals. , 2008, Journal of molecular graphics & modelling.

[8]  Ran Kivetz,et al.  Alternative Models for Capturing the Compromise Effect , 2004 .

[9]  Alessandro Giuliani,et al.  Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays , 2010, Expert opinion on drug metabolism & toxicology.

[10]  C. Portier,et al.  Optimal design of the chronic animal bioassay. , 1983, Journal of toxicology and environmental health.

[11]  Chien-Jen Chen,et al.  Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B– and C–related risk , 2003, Hepatology.

[12]  D. Dix,et al.  The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  J. Contrera,et al.  In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. , 1998, Environmental health perspectives.

[14]  National Library of Medicine and Its Toxicology and Environmental Health Information Program , 2014 .

[15]  J. Ward The Roles of the Toxicologic Pathologist in Cancer Research , 2010, Toxicologic pathology.

[16]  Hugo M Vargas,et al.  Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals , 2013, Expert opinion on drug safety.

[17]  G. Williams,et al.  Short- and intermediate-term carcinogenicity testing--a review. Part 2: available experimental models. , 1998, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[18]  D. B. McGregor,et al.  The use of short-and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. Consensus report. , 1999, IARC scientific publications.

[19]  R. Tamura,et al.  Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[20]  C. Thompson,et al.  Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  S. Orsulic,et al.  Mouse models of cancer. , 2011, Annual review of pathology.

[22]  Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. , 1987, IARC monographs on the evaluation of carcinogenic risks to humans. Supplement.

[23]  R. Tennant,et al.  The use of transgenic animals in cancer testing. , 1999, Inhalation toxicology.

[24]  M. Waters,et al.  Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. , 2010, Mutation research.

[25]  D. Rall LABORATORY ANIMAL TESTS AND HUMAN CANCER* , 2000, Drug metabolism reviews.

[26]  S. Cohen Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays , 2010, Toxicologic pathology.

[27]  J. Bucher The National Toxicology Program Rodent Bioassay , 2002 .

[28]  M. Soffritti,et al.  Ramazzini Foundation Cancer Program , 2002, Annals of the New York Academy of Sciences.

[29]  D. Gaylor,et al.  Experimental design of bioassays for screening and low dose extrapolation. , 1985, Risk Analysis.

[30]  C. Alden,et al.  The Tg rasH2 Mouse in Cancer Hazard Identification , 2002, Toxicologic pathology.

[31]  G Pearse,et al.  Prediction of Rodent Carcinogenesis: An Evaluation of Prechronic Liver Lesions as Forecasters of Liver Tumors in NTP Carcinogenicity Studies , 2004, Toxicologic pathology.

[32]  J. Haseman,et al.  The relationship between use of the maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[33]  J. Haseman,et al.  The Relationship between Use of the Maximum Tolerated Dose and Study Sensitivity for Detecting Rodent Carcinogenicity , 1994 .

[34]  S. O’Rahilly,et al.  PPAR gamma and human metabolic disease. , 2006, The Journal of clinical investigation.

[35]  John D. Walker,et al.  Global Government applications of analogues, SAR s and QSAR s to predict aquatic toxicity, chemical or physical properties, environmental fate parameters and health effects of organic chemicals , 2002, SAR and QSAR in environmental research.

[36]  J. Weisburger Carcinogenicity and mutagenicity testing, then and now. , 1999, Mutation research.

[37]  F. Belpoggi,et al.  The Scientific and Methodological Bases of Experimental Studies for Detecting and Quantifying Carcinogenic Risks , 1999, Annals of the New York Academy of Sciences.

[38]  M. V. von Wittenau,et al.  Cancer risk assessment , 1995, Science.

[39]  W Schmid,et al.  The micronucleus test. , 1975, Mutation research.

[40]  Gbo,et al.  Prediction of carcinogenic potential of substances using repeated dose toxicity data , 2012 .

[41]  R. Ponce,et al.  Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals , 2010, Toxicologic pathology.

[42]  D. Freedman,et al.  Concordance between rats and mice in bioassays for carcinogenesis. , 1996, Regulatory toxicology and pharmacology : RTP.

[43]  B. Ames,et al.  An improved bacterial test system for the detection and classification of mutagens and carcinogens. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Mary J. C. Hendrix,et al.  Reprogramming metastatic tumour cells with embryonic microenvironments , 2007, Nature Reviews Cancer.

[45]  J. French,et al.  The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  R L Kodell,et al.  A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients. , 2011, Regulatory toxicology and pharmacology : RTP.

[47]  Emilio Benfenati,et al.  The Expanding Role of Predictive Toxicology: An Update on the (Q)SAR Models for Mutagens and Carcinogens , 2007, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[48]  K Yamagiwa,et al.  Experimental study of the pathogenesis of carcinoma , 1977, CA: a cancer journal for clinicians.

[49]  L. Weisenthal,et al.  Clonogenic and nonclonogenic in vitro chemosensitivity assays. , 1985, Cancer treatment reports.

[50]  W. Stott,et al.  Mechanisms of chemical carcinogenicity , 1989 .

[51]  A. Hayes Principles and methods of toxicology , 1982 .

[52]  G. Williams,et al.  Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.

[53]  C. Alden,et al.  Improving Carcinogenicity Assessment , 2013, Toxicologic pathology.

[54]  U. Epa Guidelines for carcinogen risk assessment , 1986 .

[55]  H. Masuda,et al.  Testing for carcinogenicity of pharmaceuticals. , 1996, The Journal of toxicological sciences.

[56]  R. Shaw,et al.  Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. , 2000, Carcinogenesis.

[57]  R. Parker,et al.  Society of Toxicologic Pathology , 2014 .

[58]  Melvin E Andersen,et al.  Dose-dependent transitions in mechanisms of toxicity: case studies. , 2004, Toxicology and applied pharmacology.

[59]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[60]  Alan R. Boobis,et al.  IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .

[61]  M. Neel,et al.  The Molecular Basis of Human Cancer , 1993 .

[62]  Prashant S Khakar Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery. , 2010, Current topics in medicinal chemistry.

[63]  A. Giuliani,et al.  Exploring In Vitro/In Vivo Correlation: Lessons Learned from Analyzing Phase I Results of the US EPA's ToxCast Project , 2010, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[64]  H. Murff,et al.  Cancer risk assessment: quality and impact of the family history interview. , 2004, American journal of preventive medicine.

[65]  F. Sistare,et al.  An Evaluation of Chronic 6- and 12-Month Rat Toxicology Studies as Predictors of 2-Year Tumor Outcome , 2010, Veterinary pathology.

[66]  A. Aitio,et al.  Human Carcinogens So Far Identified , 1989, Japanese journal of cancer research : Gann.

[67]  S. Uwagawa,et al.  Case study: an evaluation of the human relevance of the synthetic pyrethroid metofluthrin-induced liver tumors in rats based on mode of action. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[68]  W. Pao,et al.  How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Haseman,et al.  Evaluation of false positive and false negative outcomes in NTP long-term rodent carcinogenicity studies. , 1996, Risk analysis : an official publication of the Society for Risk Analysis.

[70]  R. Ettlin Toxicologic Pathology in the 21st Century , 2013, Toxicologic pathology.

[71]  G. Williams,et al.  Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay. , 1998, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[72]  W. Stokes,et al.  The international symposium on regulatory testing and animal welfare: recommendations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing. , 2002, ILAR journal.

[73]  J. D. Camargo Chemical carcinogenesis – mode of action to inform quantitative human risk , 2013 .

[74]  A. Monro Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? , 1996, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[75]  Joy A. Cavagnaro,et al.  Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.

[76]  Stu Borman Drug Design On The Fast Track , 2014 .

[77]  Rajendra Mehta,et al.  Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals , 1996, Journal of cellular biochemistry. Supplement.

[78]  Ricardo Macarron,et al.  Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.

[79]  P. Infante Use of rodent carcinogenicity test results for determining potential cancer risk to humans. , 1993, Environmental health perspectives.

[80]  L. Sachs,et al.  In vitro transformation of normal cells to tumor cells by carcinogenic hydrocarbons. , 1965, Journal of the National Cancer Institute.

[81]  J. Ward The Two-Year Rodent Carcinogenesis Bioassay — Will It Survive? , 2007 .

[82]  E. Mcconnell,et al.  The Value and Significance of Life Span and Scheduled Termination Data in Long-term Toxicity and Carcinogenesis Studies , 1985, Toxicologic pathology.

[83]  Raffaella Corvi,et al.  Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop. , 2008, Mutation research.

[84]  C. Austin,et al.  Improving the Human Hazard Characterization of Chemicals: A Tox21 Update , 2013, Environmental health perspectives.

[85]  S. O’Rahilly,et al.  Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance , 2006, Cell metabolism.

[86]  R. Maronpot,et al.  The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice , 2004, Cancer Research.

[87]  J. Timbrell,et al.  Casarett and Doull's Toxicology: The Basic Science of Poisons , 1981 .

[88]  G. Williams,et al.  Application of a cellular test battery in the decision point approach to carcinogen identification. , 1988, Mutation research.

[89]  M Younes,et al.  IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.

[90]  James R. Downing,et al.  Annual review of pathology : mechanisms of disease , 2006 .

[91]  E. Weisburger Techniques for carcinogenicity studies. , 1981, Cancer research.

[92]  D. Jacobson-Kram Cancer Risk Assessment Approaches at the FDA/CDER: Is the Era of the 2-Year Bioassay Drawing to a Close? , 2010, Toxicologic pathology.

[93]  J M Ward,et al.  Factors in the evaluation of 200 National Cancer Institute carcinogen bioassays. , 1981, Journal of toxicology and environmental health.

[94]  J. Huff,et al.  Evolution of Research in Cancer Etiology , 2002 .

[95]  C. Bielza,et al.  Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes , 2012, PloS one.

[96]  C. Bolognesi,et al.  Scientific opinion on genotoxicity testing strategies applicable to food and 3 feed safety assessment , 2011 .

[97]  Valérie Zuang,et al.  Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.

[98]  M. Fenech,et al.  In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. , 2011, Mutagenesis.

[99]  A. J. Lehman,et al.  Procedures for the appraisal of the toxicity of chemicals in foods. , 1949, Food, Drug, cosmetic law quarterly.

[100]  Romualdo Benigni,et al.  Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. , 2011, Chemical reviews.

[101]  S. Plassmann,et al.  Successful Drug Development Despite Adverse Preclinical Findings Part 1: Processes to Address Issues and Most Important Findings , 2010, Journal of toxicologic pathology.

[102]  Gary M Williams,et al.  Application of mode-of-action considerations in human cancer risk assessment. , 2008, Toxicology letters.

[103]  J. Miller,et al.  The carcinogenic aminoazo dyes. , 1953, Advances in cancer research.

[104]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.

[105]  J. Waldrep,et al.  Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. , 2010, Anticancer research.

[106]  I. Lambert,et al.  Detailed review of transgenic rodent mutation assays. , 2005, Mutation research.

[107]  A. Jacobs Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[108]  S. Cohen Urinary Bladder Carcinogenesis by DNA Reactive and Non-Reactive Chemicals: Non-Linearities and Thresholds , 2012 .

[109]  B. Ames,et al.  What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database. , 1998, Drug metabolism reviews.

[110]  R. Tennant,et al.  Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. , 1996, Mutation research.

[111]  Robert J Kavlock,et al.  Incorporating biological, chemical, and toxicological knowledge into predictive models of toxicity. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[112]  G. B. Gori Regulatory Forum Opinion Piece , 2013, Toxicologic pathology.

[113]  J. Taylor,et al.  An industry perspective , 2015 .

[114]  G. Williams,et al.  The distinction between genotoxic and epigenetic carcinogens and implication for cancer risk. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[115]  Luis G Valerio,et al.  Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. , 2007, Toxicology and applied pharmacology.

[116]  Andrew P. Worth,et al.  The Role of Qsar Methodology in the Regulatory Assessment of Chemicals , 2010 .

[117]  Carolyn Vickers,et al.  IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .

[118]  J. Huff,et al.  The Limits of Two-Year Bioassay Exposure Regimens for Identifying Chemical Carcinogens , 2008, Environmental health perspectives.

[119]  J. Bucher The National Toxicology Program rodent bioassay: designs, interpretations, and scientific contributions. , 2002, Annals of the New York Academy of Sciences.

[120]  M. Long Predicting carcinogenicity in humans: The need to supplement animal-based toxicology , 2006 .

[121]  R B Conolly,et al.  A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. , 1995, Cancer letters.

[122]  Trevor Green,et al.  Case study: weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[123]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[124]  Frank D Sistare,et al.  Use of Transgenic Mice in Carcinogenicity Hazard Assessment , 2004, Toxicologic pathology.

[125]  B. Leblanc,et al.  Pathology and Tissue Sampling Protocols for Rodent Carcinogenicity Studies: Time for Revision , 2000, Toxicologic pathology.

[126]  R. Tennant,et al.  Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment , 2000 .

[127]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[128]  Vicki L Dellarco,et al.  A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[129]  David M. Reif,et al.  Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. , 2012, Chemical research in toxicology.

[130]  Ord,et al.  Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens , 2013 .

[131]  F. D. De Braud,et al.  Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer , 2003, Pharmacological Reviews.

[132]  C. Alden,et al.  A Critical Appraisal of the Value of the Mouse Cancer Bioassay in Safety Assessment , 1996, Toxicologic pathology.

[133]  A. Wakata,et al.  Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance. , 2008, The Journal of toxicological sciences.

[134]  David W Gaylor,et al.  Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? , 2005, Regulatory toxicology and pharmacology : RTP.

[135]  Kathryn Z. Guyton,et al.  Mode of Action Frameworks: A Critical Analysis , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[136]  G. Williams,et al.  The decision-point approach for systematic carcinogen testing. , 1981, Food and cosmetics toxicology.

[137]  S. Cohen,et al.  Alternative models for carcinogenicity testing. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[138]  Lester B Lave,et al.  Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. , 2003, Regulatory toxicology and pharmacology : RTP.

[139]  John R. Bucher,et al.  Conflicting Views on Chemical Carcinogenesis Arising from the Design and Evaluation of Rodent Carcinogenicity Studies , 2007, Environmental health perspectives.

[140]  Robert J Kavlock,et al.  Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program , 2012, Systems biology in reproductive medicine.

[141]  R. Storer,et al.  An Industry Perspective on the Utility of Short-Term Carcinogenicity Testing in Transgenic Mice in Pharmaceutical Development , 2010, Toxicologic pathology.

[142]  J. Huff Chemicals Studied and Evaluated in Long‐Term Carcinogenesis Bioassays by Both the Ramazzini Foundation and the National Toxicology Program , 2002, Annals of the New York Academy of Sciences.

[143]  G. Williams,et al.  Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological Studies , 2007, Critical reviews in toxicology.

[144]  T. Pastoor,et al.  Historical perspective of the cancer bioassay. , 2005, Scandinavian journal of work, environment & health.

[145]  Mark Fowler,et al.  Food Safety Modernization Act , 2013 .

[146]  S. Plassmann,et al.  Successful Drug Development Despite Adverse Preclinical Findings Part 2: Examples , 2010, Journal of toxicologic pathology.

[147]  Daniel Morton,et al.  An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing , 2011, Toxicologic pathology.

[148]  G. Williams,et al.  IFSTP guidelines for the design and interpretation of the chronic rodent carcinogenicity bioassay. , 1992, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[149]  Robert A. Baan,et al.  The Science and Practice of Carcinogen Identification and Evaluation , 2004, Environmental health perspectives.

[150]  P. Nambiar,et al.  The rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals , 2013, Toxicologic pathology.

[151]  David Kirkland,et al.  A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. , 2011, Mutation research.

[152]  R. Hoffman In vitro sensitivity assays in cancer: A review, analysis, and prognosis , 1991, Journal of clinical laboratory analysis.

[153]  Expectations for Transgenic Rodent Cancer Bioassay Models , 2001, Toxicologic pathology.

[154]  J. P. Van Oosterhout,et al.  The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. , 1997, Regulatory toxicology and pharmacology : RTP.

[155]  J. Butel,et al.  The history of tumor virology. , 2008, Cancer research.

[156]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[157]  Christopher Portier,et al.  Human carcinogenic risk evaluation, Part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[158]  Bas J Blaauboer,et al.  An expert consortium review of the EC-commissioned report "alternative (Non-Animal) methods for cosmetics testing: current status and future prospects - 2010". , 2011, ALTEX.

[159]  J. Haseman,et al.  The role of transgenic mouse models in carcinogen identification. , 2002, Environmental health perspectives.

[160]  Ocspp,et al.  PRN 96-5: Interim Use of the Proposed Guidelines for Carcinogen Risk Assessment , 2014 .

[161]  Draft OECD Guideline for the Testing of Chemicals , 2006 .

[162]  C L Alden,et al.  A Critical Review of the Effectiveness of Rodent Pharmaceutical Carcinogenesis Testing in Predicting for Human Risk , 2011, Veterinary pathology.

[163]  Douglas C. Wolf,et al.  Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions , 2009, Toxicologic pathology.

[164]  I C Munro,et al.  Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs. , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[165]  Paul L. Carmichael,et al.  Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs , 2011, Mutagenesis.

[166]  Samuel M Cohen,et al.  Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[167]  Fuart Gatnik Mojca,et al.  Review of QSAR Models and Software Tools for Predicting of Genotoxicity and Carcinogenicity , 2010 .

[168]  S. Cohen An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[169]  B. Ames,et al.  Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[170]  J H Weisburger,et al.  Carcinogen testing: current problems and new approaches. , 1981, Science.

[171]  V. Strauss,et al.  Best Practices for Clinical Pathology Testing in Carcinogenicity Studies , 2011, Toxicologic pathology.

[172]  A. Goldberg,et al.  Alternatives in toxicology , 2006 .

[173]  R. Tennant,et al.  Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. , 1995, Environmental health perspectives.

[174]  Jennifer Seed,et al.  A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.

[175]  J. D. de Camargo Chemical carcinogenesis – mode of action to inform quantitative human risk , 2013, BMC Proceedings.

[176]  E Spencer Williams,et al.  The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH. , 2009, Regulatory toxicology and pharmacology : RTP.

[177]  A. Jacobs,et al.  History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals , 2013, Veterinary pathology.

[178]  J. Contrera,et al.  Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. , 1997, Regulatory toxicology and pharmacology : RTP.

[179]  Nicola J Hewitt,et al.  International prevalidation studies of the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility. , 2010, Mutation research.

[180]  L. Bernstein,et al.  Target organs in chronic bioassays of 533 chemical carcinogens. , 1991, Environmental health perspectives.

[181]  C. Capen,et al.  Neoplastic Lesions of Questionable Significance to Humans , 1994, Toxicologic pathology.

[182]  Albrecht Poth,et al.  Bhas42 cell transformation assay as a predictor of carcinogenicity , 2008 .

[183]  Romualdo Benigni,et al.  Alternative strategies for carcinogenicity assessment: an efficient and simplified approach based on in vitro mutagenicity and cell transformation assays. , 2011, Mutagenesis.

[184]  J. Heddle,et al.  The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. , 1976, Mutation research.

[185]  J H Weisburger,et al.  Systematic carcinogen testing through the decision point approach. , 1981, Annual review of pharmacology and toxicology.

[186]  The National Library of Medicine and its role. , 1993 .

[187]  M D Waters,et al.  Short-term tests for defining mutagenic carcinogens. , 1999, IARC scientific publications.

[188]  G. Jena,et al.  Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: A review on current status , 2005 .

[189]  S. O’Rahilly,et al.  PPARγ and human metabolic disease , 2006 .

[190]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[191]  Harald Enzmann,et al.  Principles of Testing for Carcinogenic Activity , 2007 .